- Poster presentation
- Open Access
Genotypic susceptibility to tipranavir of HIV-1 isolates in treatment-experienced patients
© Piliero et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Resistance Testing
- Phenotypic Susceptibility
- Potential Therapeutic Option
- Protease Inhibitor Resistance
Tipranavir (TPV) is a ritonavir-boosted HIV protease inhibitor (PI) indicated for use in treatment-experienced patients (TEP) with PI resistance. TPV has shown superior virologic and immunologic responses in TEPs compared with first-generation PIs. In the Utilization of HIV Drug Resistance in Treatment-Experienced Patients (UTILIZE) study, we assessed the presence of susceptibility to TPV among HIV-1 isolates in TEPs.
UTILIZE was conducted at 40 US sites and examined clinician use of HIV drug-resistance testing in TEPs failing a PI-based regimen. In this observational study, patients were randomized to have either a genotype (GT; Monogram GeneSeq) or combined phenotype-genotype test (PGT; Monogram Phenosense GT) to assist with treatment decision-making. Resistance data were evaluated to assess TPV susceptibility among isolates from patients failing a PI-based regimen.
Genotypic TPV susceptibility* (n = 139)
Phenotypic TPV susceptibility** (n = 69)
1–2 previous PIs
3–4 previous PIs
5+ previous PIs
In this cohort of TEPs failing a PI-based regimen, a majority of patient isolates showed full or partial susceptibility to TPV. Even in the most PI-experienced patients, one-third to one-half had virus that remained fully or partially susceptible to TPV. An advantage of phenotypic testing is that it reports both full and partial drug susceptibility which may help guide clinician choice of TPV. When constructing a new regimen in PI-experienced patients, resistance testing should guide the use of TPV as a potential therapeutic option.
This article is published under license to BioMed Central Ltd.